Skip to contentB
BioCorRx Inc.
B
BICXBioCorRx Inc. Q3 2024 · 10-Q
Revenue$0.00$0.00−100.0% vs Q3 2023 Net Income-$1.51M-$1.51MN/M vs Q3 2023 EPS Diluted-$0.14-$0.14no prior Q3 2023 on file Operating Income-$1,659,721N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioCorRx Inc. · CIK 1443863 · Engraved from SEC EDGAR
derived
ended Sep 30, 2024 · filed Nov 14, 2024 · 45 d after period end